AUSTRALIAN medicinal cannabis drug developer Bod Science launched its full-spectrum extract last week.
It is called MediCabilis TM CBG 50 standardised to 50mg of the active cannabigerol (CBG) per mL.
The potential for therapeutic application of CBG has been found for several conditions, such as fibromyalgia, inflammatory bowel disease, Alzheimer's disease, multiple sclerosis, and anxiety.
Preliminary results of an observational project have shown increases in the percentage of change from baseline for anxiety, depression, fatigue, sleep disturbance, and pain, with noticeable improvements after weeks and the highest results for most conditions after four months of taking CBG.
While the cannabis constituents CBD and THC have been investigated, research on CBG is relatively new.
CBG shares many similarities with CBD.
Preclinical studies indicate a good safety profile, with no acute toxicity up to 200mg per kg, and no reported toxicity with long-term use.
MediCabilis TM CBG 50, 25mL bottle with syringe wholesales for $220 and has a RRP of $250.
Bod Science also plans to set up a manufacturing facility in Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jan 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jan 23
